Who are Sacubitril / Valsartan Oral Tablet [Entresto]'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sacubitril-valsartan-oral-tablet-entresto.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Sacubitril / Valsartan Oral Tablet [Entresto] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sacubitril / Valsartan Oral Tablet [Entresto] (Sacubitril / Valsartan Oral Tablet [Entresto]) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE2 activator and angiotensin II receptor antagonist. Area: Cardiovascular.

phase 3 ACE2 activator and angiotensin II receptor antagonist ACE2 and AT1R Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sacubitril / Valsartan Oral Tablet [Entresto] (Sacubitril / Valsartan Oral Tablet [Entresto]) — University Hospital, Grenoble. Sacubitril is an angiotensin-converting enzyme 2 (ACE2) activator, while valsartan is an angiotensin II receptor antagonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sacubitril / Valsartan Oral Tablet [Entresto] TARGET	Sacubitril / Valsartan Oral Tablet [Entresto]	University Hospital, Grenoble	phase 3	ACE2 activator and angiotensin II receptor antagonist	ACE2 and AT1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE2 activator and angiotensin II receptor antagonist class)

University Hospital, Grenoble · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sacubitril / Valsartan Oral Tablet [Entresto] — Competitive Intelligence Brief. https://druglandscape.com/ci/sacubitril-valsartan-oral-tablet-entresto. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab